PMID- 19937366
OWN - NLM
STAT- MEDLINE
DCOM- 20100908
LR  - 20220330
IS  - 1573-7373 (Electronic)
IS  - 0167-594X (Linking)
VI  - 98
IP  - 1
DP  - 2010 May
TI  - The expression level of sphingosine-1-phosphate receptor type 1 is related to 
      MIB-1 labeling index and predicts survival of glioblastoma patients.
PG  - 41-7
LID - 10.1007/s11060-009-0064-5 [doi]
AB  - Although there are many reports on the clinical use of the MIB-1 labeling index 
      (LI), which is a measure of proliferative activity in astrocytomas; its 
      significance varies between studies. There are no known molecules that are 
      directly linked to the MIB-1 LI in astrocytomas. We evaluated the clinical value 
      of the MIB-1 LI in our human glioblastoma cases and determined the molecules that 
      possibly influenced the MIB-1 LI. An immunohistochemical study of the MIB-1 
      protein was performed and MIB-1 LIs of 38 glioblastomas were determined. In the 
      same cases, epidermal growth factor receptor (EGFR), platelet-derived growth 
      factor receptor-alpha (PDGFRA), and sphingosine-1-phosphate receptor type 1 
      (S1P(1)), which are known regulators of glioma cell proliferation, were detected 
      and quantified by quantitative real-time-PCR or western blotting. Kaplan-Meier 
      survival curves for 38 patients with glioblastomas showed that a high MIB-1 LI 
      correlated with poor survival (P < 0.05). Among the molecules tested, only the 
      low expression of S1P(1) was significantly correlated with the high MIB-1 LI in 
      glioblastomas (P < 0.05). Multivariate analysis revealed that the S1P(1) 
      expression level was a significant prognostic factor. Our results indicate that 
      the MIB-1 LI is an important prognostic factor in human glioblastomas. 
      Furthermore, downregulation of S1P(1) expression increases proliferative 
      activity, and thus enhances the malignancy of glioblastomas, resulting in a poor 
      survival.
FAU - Yoshida, Yuya
AU  - Yoshida Y
AD  - Department of Neurosurgery, Graduate School of Medical Science, Kanazawa 
      University, 13-1 Takara-machi, Kanazawa, 920-8641, Japan.
FAU - Nakada, Mitsutoshi
AU  - Nakada M
FAU - Harada, Tomoya
AU  - Harada T
FAU - Tanaka, Shingo
AU  - Tanaka S
FAU - Furuta, Takuya
AU  - Furuta T
FAU - Hayashi, Yasuhiko
AU  - Hayashi Y
FAU - Kita, Daisuke
AU  - Kita D
FAU - Uchiyama, Naoyuki
AU  - Uchiyama N
FAU - Hayashi, Yutaka
AU  - Hayashi Y
FAU - Hamada, Jun-ichiro
AU  - Hamada J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20091125
PL  - United States
TA  - J Neurooncol
JT  - Journal of neuro-oncology
JID - 8309335
RN  - 0 (Antibodies, Antinuclear)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (MIB-1 antibody)
RN  - 0 (Receptors, Lysosphingolipid)
RN  - 0 (S1PR1 protein, human)
RN  - 0 (Sphingosine-1-Phosphate Receptors)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Antibodies, Antinuclear
MH  - *Antibodies, Monoclonal
MH  - Brain Neoplasms/classification/*metabolism/*mortality
MH  - Child
MH  - Female
MH  - Glioblastoma/classification/*metabolism/*mortality
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Karnofsky Performance Status
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Receptors, Lysosphingolipid/genetics/*metabolism
MH  - Retrospective Studies
MH  - Sphingosine-1-Phosphate Receptors
MH  - Statistics as Topic
MH  - Young Adult
EDAT- 2009/11/26 06:00
MHDA- 2010/09/09 06:00
CRDT- 2009/11/26 06:00
PHST- 2009/09/07 00:00 [received]
PHST- 2009/11/08 00:00 [accepted]
PHST- 2009/11/26 06:00 [entrez]
PHST- 2009/11/26 06:00 [pubmed]
PHST- 2010/09/09 06:00 [medline]
AID - 10.1007/s11060-009-0064-5 [doi]
PST - ppublish
SO  - J Neurooncol. 2010 May;98(1):41-7. doi: 10.1007/s11060-009-0064-5. Epub 2009 Nov 
      25.